Medication Review During Annual Geriatric Visits: A Comprehensive Clinical Perspective

Abstract

Medication review during annual geriatric visits is an essential component of comprehensive care for older adults, aimed at optimizing pharmacotherapy, minimizing polypharmacy, and reducing adverse drug events. This review synthesizes current evidence, mechanisms, and guideline-based practices to inform clinicians on best approaches for medication assessment, risk mitigation, and personalized management in elderly populations. The article emphasizes the epidemiology of polypharmacy, pathophysiological changes with aging, risk factors for medication-related problems, clinical features suggestive of adverse drug reactions, diagnostic approaches, treatment strategies, and recent advances in geriatric pharmacotherapy. Practical implications and recommendations for integrating medication review into routine geriatric care are discussed, providing a robust framework for improving patient safety and therapeutic outcomes.

Introduction

With the global increase in life expectancy, the geriatric population is expanding, presenting unique challenges for healthcare systems. Older adults are at heightened risk for chronic diseases, often requiring complex pharmacological regimens. Annual geriatric visits offer a strategic opportunity to review medications, address polypharmacy, and prevent adverse drug events (ADEs). Medication review is a systematic, evidence-informed process to evaluate current pharmacotherapy, assess appropriateness, and implement changes for optimal patient outcomes. This article provides a scientific and clinically relevant overview of medication review during annual geriatric assessments, integrating recent research, guideline recommendations, and practical clinical insights.

Epidemiology / Disease Burden

Polypharmacy, commonly defined as the concurrent use of five or more medications, affects over 40% of adults aged 65 years and older in developed countries. Studies indicate that up to 20% of older adults experience at least one ADE annually, with medication-related hospitalizations accounting for a significant portion of emergency admissions in this demographic. The prevalence of potentially inappropriate medications (PIMs) is substantial, with research demonstrating that 30–50% of elderly patients are prescribed at least one PIM, as identified by criteria such as Beers or STOPP/START. The burden of medication errors, drug-drug interactions, and non-adherence further complicates disease management and increases healthcare costs.

Pathophysiology

Aging is associated with physiological changes that alter drug pharmacokinetics and pharmacodynamics. Decreased renal and hepatic function, changes in body composition (such as increased fat-to-lean mass ratio), reduced gastrointestinal absorption, and altered protein binding impact drug metabolism and elimination. These factors increase susceptibility to drug accumulation and toxicity. Moreover, the aging brain is more sensitive to sedatives, anticholinergics, and psychotropics, thereby increasing the risk of cognitive impairment and falls. Understanding these mechanisms is crucial for tailoring pharmacotherapy and preventing iatrogenic complications in elderly patients.

Risk Factors

Several risk factors predispose older adults to medication-related problems. These include advanced age, multiple chronic conditions, cognitive impairment, poor renal or hepatic function, low health literacy, and the use of multiple healthcare providers. Socioeconomic factors, such as limited access to healthcare or support services, further exacerbate risk. Polypharmacy itself is both a risk factor and a consequence of inadequate medication review, leading to a cycle of increasing medication burden and vulnerability to ADEs.

Clinical Features

Clinical manifestations of medication-related problems in the elderly are often nonspecific and may mimic age-related decline or disease progression. Common features include falls, delirium, cognitive dysfunction, orthostatic hypotension, gastrointestinal disturbances, and unexplained changes in functional status. Adverse drug reactions can present atypically, making high clinical suspicion and regular medication review essential. Clinicians should be vigilant for new or worsening symptoms following medication changes or additions.

Diagnosis

Diagnosis of medication-related problems requires a thorough history, medication reconciliation, and review of clinical records. A systematic approach includes assessing all prescribed, over-the-counter, and complementary medicines. The use of explicit criteria (e.g., Beers, STOPP/START, and the Medication Appropriateness Index) assists in identifying PIMs and potential drug-drug or drug-disease interactions. Laboratory monitoring and functional assessments (e.g., cognitive screening, fall risk evaluation) complement the diagnostic process. Collaboration with pharmacists and other healthcare professionals enhances diagnostic accuracy and comprehensive care.

Treatment & Management

Management centers on optimizing medication regimens, deprescribing unnecessary or harmful drugs, and individualizing therapy based on patient goals, comorbidities, and life expectancy. The process involves shared decision-making, patient and caregiver education, and regular monitoring for efficacy and safety. Non-pharmacological interventions should be prioritized where appropriate. Integration of clinical decision tools and multidisciplinary team input, including pharmacists and geriatricians, enhances the effectiveness and safety of medication management.

Recent Advances / Emerging Therapies

Recent developments in geriatric pharmacotherapy include the use of electronic prescribing systems with integrated clinical decision support, which help identify potential interactions and inappropriate prescriptions. Pharmacogenomic testing is emerging as a tool to tailor drug therapy based on genetic variability in drug metabolism. Mobile health (mHealth) applications and telemedicine platforms facilitate remote medication monitoring and adherence support. Research is ongoing into deprescribing protocols and implementation strategies to reduce polypharmacy without compromising disease control.

Guideline Recommendations

International guidelines from bodies such as the American Geriatrics Society and the European Geriatric Medicine Society advocate for annual comprehensive medication reviews in all older adults. Key recommendations include routine use of validated screening tools for PIMs, regular assessment of renal and hepatic function, and incorporation of patient preferences into therapeutic decisions. Guidelines emphasize the importance of deprescribing, especially for medications with anticholinergic or sedative properties, and recommend ongoing education for healthcare providers in geriatric pharmacology.

Conclusion

Medication review during annual geriatric visits is a cornerstone of quality care for older adults, offering substantial benefits in reducing polypharmacy, preventing adverse events, and personalizing treatment. By integrating evidence-based strategies, multidisciplinary collaboration, and patient-centered approaches, clinicians can optimize pharmacotherapy and enhance health outcomes in this vulnerable population. Ongoing research, technological advances, and adherence to guideline recommendations will continue to refine and improve the process of medication review in geriatric practice.